By Rory Gallivan
GlaxoSmithKline PLC (GSK.LN) and Theravance Inc (THRX) Wednesday
said two phase III studies of its chronic obstructive pulmonary
disease treatment Incruse Ellipta showed an improvement in lung
function compared with studies on patients taking a placebo.
"These data are an important addition to the evidence base
supporting the efficacy and safety of Incruse," said Darrell Baker,
head of Global Respiratory Franchise at GlaxoSmithKline.
"These studies are also the first to investigate the combined
effect of two of the newest medicines from our respiratory
portfolio, both of which provide 24-hour efficacy," he added.
Shares at 1137 GMT, up 3 pence, or 0.2%, at 1,609 pence valuing
the company at 78.1 billion pounds ($131.1 billion).
Write to Rory Gallivan at rory.gallivan@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires